Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

被引:149
作者
Rodriguez-Novoa, S
Barreiro, P
Rendón, A
Jiménez-Nacher, I
González-Lahoz, J
Soriano, V
机构
[1] Hosp Carlos III, Pharmacokinet Unit, Madrid, Spain
[2] Hosp Carlos III, Infect Dis Serv, Madrid, Spain
关键词
D O I
10.1086/429327
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We examined 516G>T polymorphisms at the gene encoding the cytochrome P450 in 100 human immunodeficiency virus positive subjects who were receiving efavirenz (EFV). Elevated plasma EFV concentrations were found in 40% of subjects with the polymorphic homozygous genotype and 19% of subjects with the heterozygous genotype. Conversely, 20% of subjects with the wild-type genotype had subtherapeutic concentrations of EFV. CYP2B6-516 genotyping may help to identify subjects who have plasma EFV concentrations that are outside of the therapeutic range.
引用
收藏
页码:1358 / 1361
页数:4
相关论文
共 14 条
[1]   Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz [J].
Gallego, L ;
Barreiro, P ;
del Río, R ;
de Requena, DG ;
Rodríguez-Albariño, A ;
González-Lahoz, J ;
Soriano, V .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (03) :430-432
[2]  
HAAS D, 2004, 11 C RETR OPP INF SA, P124
[3]   Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:: 2003 recommendations of an international AIDS Society-USA panel [J].
Hirsch, MS ;
Brun-Vézinet, F ;
Clotet, B ;
Conway, B ;
Kuritzkes, DR ;
D'Aquila, RT ;
Demeter, LM ;
Hammer, SM ;
Johnson, VA ;
Loveday, C ;
Mellors, JW ;
Jacobsen, DM ;
Richman, DD .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (01) :113-128
[4]   Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver [J].
Lang, T ;
Klein, K ;
Fischer, J ;
Nüssler, AK ;
Neuhaus, P ;
Hofmann, U ;
Eichelbaum, M ;
Schwab, M ;
Zanger, UM .
PHARMACOGENETICS, 2001, 11 (05) :399-415
[5]   Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity [J].
Martin, AM ;
Nolan, D ;
Gaudieri, S ;
Phillips, E ;
Mallal, S .
PHARMACOGENOMICS, 2004, 5 (06) :643-655
[6]   Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients [J].
Marzolini, C ;
Telenti, A ;
Decosterd, LA ;
Greub, G ;
Biollaz, J ;
Buclin, T .
AIDS, 2001, 15 (01) :71-75
[7]   Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans [J].
Mouly, S ;
Lown, KS ;
Kornhauser, D ;
Joseph, JL ;
Fiske, WD ;
Benedek, IH ;
Watkins, PB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (01) :1-9
[8]  
Mutlib AE, 1999, DRUG METAB DISPOS, V27, P1319
[9]   Gender difference in ifosfamide metabolism by human liver microsomes [J].
Schmidt, R ;
Baumann, F ;
Hanschmann, H ;
Geissler, F ;
Preiss, R .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2001, 26 (03) :193-200
[10]   Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography [J].
Tribut, O ;
Arvieux, C ;
Michelet, C ;
Chapplain, JM ;
Allain, H ;
Bentué-Ferrer, D .
THERAPEUTIC DRUG MONITORING, 2002, 24 (04) :554-562